[Form 4] The Chemours Company Insider Trading Activity

Rhea-AI Filing Summary

Denise Dignam, President & CEO and director of The Chemours Company (CC), purchased common stock on 08/08/2025. The Form 4 shows a purchase of 4,068 shares at a price of $12.06 per share, bringing her total reported beneficial ownership to 191,546.1549 shares. The filing notes the reported total includes directly owned shares, restricted stock units and dividend equivalent units.

The disclosure is a standard Section 16 insider report of a non-derivative acquisition and was submitted via Form 4. No options, conversions or derivative transactions are reported on this filing.

Positive

• Insider purchase by CEO — Denise Dignam acquired 4,068 shares of Chemours common stock.
• Purchase price disclosed — the shares were bought at $12.06 per share.
• Total beneficial ownership reported — holdings increased to 191,546.1549 shares, including direct shares, restricted stock units and dividend equivalent units.

Negative

• None.

Insights

Financial Analyst

TL;DR: CEO purchased 4,068 Chemours shares at $12.06, modestly increasing direct ownership to 191,546.1549 shares — a positive insider buy signal.

The transaction is a straightforward open-market purchase recorded on a Form 4. At $12.06 per share, the acquisition size is modest relative to institutional holdings but is meaningful as a direct purchase by the company’s CEO and a serving director. Insider purchases can be interpreted as a signal of management confidence in near-term company prospects. The filing also clarifies that the reported total ownership aggregates direct holdings, restricted stock units and dividend equivalent units, which affects the composition but not the headline share count.

Corporate Governance Expert

TL;DR: Routine Form 4 disclosure of an insider purchase by an executive-director; procedurally compliant and informative for governance monitoring.

This Form 4 provides required transparency about a senior executive’s equity purchases. It lists the reporting person’s roles (Director and President & CEO) and quantifies post-transaction holdings. From a governance standpoint, the filing meets disclosure expectations and the explanatory footnote on included share types clarifies the basis of the beneficial ownership total. There is no additional governance event or change disclosed.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dignam Denise

(Last) (First) (Middle)

C/O THE CHEMOURS COMPANY

1007 MARKET STREET

(Street)

WILMINGTON DE 19801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Chemours Co [ CC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/08/2025		P		4,068	A	$12.06	191,546.1549	D(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes directly owned shares, restricted stock units and dividend equivalent units.

	/s/ Eric Stein, Attorney-in-Fact	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.